The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1644
February 21, 2022
View Complete Issue         Table of Contents 2019 
Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
February 21, 2022 (Issue: 1644)
Odevixibat (Bylvay – Albireo), an oral ileal bile acid transporter (IBAT) inhibitor, has been approved by the FDA for treatment of pruritus in patients ≥3 months old with progressive familial intrahepatic cholestasis (PFIC). It is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Odevixibat (Bylvay) for Progressive Familial Intrahepatic Cholestasis-Associated Pruritus
Article code: 1644c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.